2023年4月23-26日,第49届欧洲血液与骨髓移植年会(EBMT 2023)于法国巴黎隆重召开。作为久负盛名的国际造血干细胞移植领域盛会,EBMT汇集全球专家学者,聚焦学术前沿热点,引领临床实践革新,不断推动学科高水平创新与发展。
编者按:2023年4月23-26日,第49届欧洲血液与骨髓移植年会(EBMT 2023)于法国巴黎隆重召开。作为久负盛名的国际造血干细胞移植领域盛会,EBMT汇集全球专家学者,聚焦学术前沿热点,引领临床实践革新,不断推动学科高水平创新与发展。在今年EBMT年会中,来自中国专家的研究继续闪耀于国际舞台,共有多达60~80项左右的中国研究被大会入选,彰显了我国血液研究的日新月异的动态,《肿瘤瞭望》特随机节选了其中17项进行了展示,以供参考。
摘要号:OS11-06
标题:LONG-TERM SURVIVAL AND TREATMENT RELATED TOXICITIES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA WITH PREVIOUS CHIMERIC ANTIGEN RECEPTOR-MODIFIED T-CELL THERAPY
在既往接受CAR-T治疗的急性淋巴细胞白血病患者中,异基因造血干细胞移植的长期生存及治疗相关毒性研究
报告人:Luxin Yang
摘要号:OS01-05
标题:ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR EARLY PRECURSOR T-CELL(ETP)AND NEAR-ETP ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA(ALL/LBL)IN REMISSION:A MULTICENTER PHASE III STUDY
异基因造血干细胞移植治疗早期前体T细胞(ETP)和急性淋巴细胞白血病/淋巴瘤(ALL/LBL)缓解期的多中心III期研究
报告人:王昱
摘要号:OS20-05
标题:LONG-TERM SAFETY AND EFFICACY OF CD38-TARGETED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA:A SINGLE-ARM,OPEN-LABEL,PHASE 1-2 TRIAL
CD38靶向嵌合抗原受体T细胞治疗复发/难治性急性髓系白血病的长期安全性和有效性:一项单臂、开放标签、1-2期试验
报告人:Xiaowen Tang
摘要号:OS06-04
标题:COMPARATIVE STUDY FOR HAPLO-,MSD AND MUD ALLO-HCTS FOR AML PATIENTS WITH KMT2A REARRANGEMENT:A STUDY ON BEHALF OF THE EBMT GLOBAL COMMITTEE AND ALWP
AML合并KMT2A重排患者单倍型、MSD和MUD-ALLO-HCTS的比较研究:代表EBMT全球委员会和ALWP的研究
报告人:Yishan Ye
摘要号:OS18-05
COMPARABLE OUTCOMES FOLLOWING NON-FIRST-DEGREE AND FIRST-DEGREE RELATED DONOR HAPLO-HCT FOR ACUTE LEUKEMIA PATIENTS IN CR:A STUDY FROM THE GLOBAL COMMITTEE AND ALWP OF EBMT
非一级和一级相关供体HAPLO-HCT治疗CR急性白血病患者的可比结果:全球委员会和EBMT的ALWP的一项研究
报告人:Yishan Ye
摘要号:351
标题:Chidamide Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation for T cell Acute Lymphoblastic Leukemia
急性T淋巴细胞白血病异基因造血干细胞移植后西达本胺的维持治疗
报告人:曹星玉
摘要号:352
标题:Comparisons of ATG-Thymoglobulin(ATG-T)with ATG-Fresenius(ATG-F)to Optimize Conditioning Regimens for Haploidentical Hematopoietic Stem Cell Transplantation(HSCT)in T-cell Acute Lymphoblastic Leukemia
急性T淋巴细胞白血病单倍型造血干细胞移植ATG-G和ATG-F优化比较研究
报告人:曹星玉
摘要号:P751
标题:A Personalized Biomarker-Targeted CAR-T Therapy is Possible Based on Immunophenotype for Acute Myeloid Leukemia Patients
AML患者有望根据免疫表型分别选择个体化CAR-T方案
报告人:宫美维
摘要号:P765
标题:An Efficient and Simple Multiparameter Flow Cytometry Protocol to Detect Minimal Residual Disease(MRD)for Acute Myeloid Leukemia(AML)
一个高效简单的多参数流式细胞术检测AML MRD方案
报告人:李珂
摘要号:P770
标题:Venetoclax,Chidamide,and Decitabine as a Bridging Therapy in Relapsed/Refractory T Lymphoblastic Cell Lymphomas with Large Mediastinal Masses Prior to CD7 CAR-T Cell Therapy
CD7 CAR-T细胞治疗前桥接维奈克拉,西达本胺和地西他滨治疗伴有纵隔大包块的复发/难治T淋巴母细胞淋巴瘤
报告人:黄乐富
摘要号:947
标题:Comparing the Prognosis of Acute Lymphoblastic Leukemia Patients Bridging to A Second Allogeneic Hematopoietic Stem Cell Transplantation Following Chimeric Antigen Receptor T-cell Therapy vs Traditional Chemotherapy
比较急性淋巴细胞白血病患者CAR-T后二次移植和化疗后二次移植预后的不同
报告人:卢岳
摘要号:P1110
标题:The Addition of Thiotepa to Haplo-hematopoietic Stem Cell Transplantation for Treatment of Acute Leukemia with Extramedullary Lesions is Safe and Effective
半相合造血干细胞移植治疗急性白血病伴髓外病变者,加用塞替哌安全且有效
报告人:赵玮
摘要号:P1153
标题:Comparisons of Safety and Efficacy of Allo-HSCT after CAR T-Cell or Chemotherapy-based Complete Remission in Pediatric T-ALL
儿童T-ALL患者行CD7 CAR-T细胞治疗或化疗后完全缓解行异基因造血干细胞移植的安全性和疗效比较
报告人:孙瑞娟
摘要号:P595
THE EFFICACY AND SAFETY OF MODERATE-DOSE AZACYTIDINE FOR MAINTENANCE THERAPY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOID MALIGNANCY
异基因干细胞移植后中剂量氮胞苷维持治疗髓系恶性肿瘤的疗效和安全性
报告人:姜尔烈
摘要号:P178
标题:Efficacy and toxicity for CD7 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory T-cell lymphoma
CD7 CAR-T疗法治疗复发难治T细胞淋巴瘤的疗效与毒性
报告人:苏国爱
摘要号:P271
标题:Combination of InotuzumabOzogamicin and Olverembatinib as Salvage Therapy for Elderly Patients with Relapsed and Refractory Ph+B-ALL
奥加伊妥珠单抗联合奥雷巴替尼挽救性治疗老年复发/难治费城染色体阳性急性B淋巴细胞白血病
报告人:林跃辉
P268 A real-world study of lenalidomide combined with low-dose venecla in maintenance therapy after allogeneic hematopoietic stem cell transplantation for recurrent and refractory hematological malignancies
来那度胺联合低剂量维奈克拉用于复发难治血液肿瘤异基因造血干细胞移植后维持治疗的真实世界研究
报告人:李智慧